(Total Views: 685)
Posted On: 09/04/2020 6:58:51 AM
Post# of 154062
Re: KenChowder #54130
KenC,
This researcher knows that Alzheimer’s disease (AD) is a process of neuroinflammation.
Leronlimab is expected to be effective in treating AD by blocking CCR5. This stops Microglia activation(macrophage-like cells resident in the brain which express CCR5), T cell migration, and the resulting chronic/hyper inflammation. This inflammation is central to AD development.
AD research and pharmacological development has shifted over the last decade or so from attacking Tau protein and beta amyloid plaques to addressing the root cause of inflammation.
Fighting plaques tau protein with stopping inflammation is like fighting ash rather than putting out the fire.
Here is an article that address CCR5 and Alzheimer’s.
Another long but very well written article.
Entanglement of CCR5 and Alzheimer’s Disease
https://www.frontiersin.org/articles/10.3389/...00209/full
This researcher knows that Alzheimer’s disease (AD) is a process of neuroinflammation.
Leronlimab is expected to be effective in treating AD by blocking CCR5. This stops Microglia activation(macrophage-like cells resident in the brain which express CCR5), T cell migration, and the resulting chronic/hyper inflammation. This inflammation is central to AD development.
AD research and pharmacological development has shifted over the last decade or so from attacking Tau protein and beta amyloid plaques to addressing the root cause of inflammation.
Fighting plaques tau protein with stopping inflammation is like fighting ash rather than putting out the fire.
Here is an article that address CCR5 and Alzheimer’s.
Another long but very well written article.
Entanglement of CCR5 and Alzheimer’s Disease
https://www.frontiersin.org/articles/10.3389/...00209/full
(6)
(0)
